Fundamentals of Business

How do investors decide where to Invest?

Industry profile

Helps to gain an insight into the evolution of the industry and competitive dynamics prevalent in the market. It discusses the significant developments in the industry and analyzes the key trends and issues. The profile provides inputs in strategic business planning of industry professionals. This profile is of immense help to management consultants, analysts, market research organizations and corporate advisors.
The objective and scope of various sections of industry profile are:
√ Industry Snapshot
This section gives a holistic overview of the industry. It starts with defining the market and goes on to give historical and current market size figures. It also clearly illustrates the major segments of the market.
√ Industry Analysis
It involves a comprehensive analysis of the industry and its market segments. This section discusses the key developments that have taken place in the industry. It also identifies and analyzes the driving factors and challenges of the industry. A description of the regulatory structure tells us about the major regulatory bodies, laws and government policies.
√ Country Analysis
This section presents the key facts&figures of the country. It also discusses the political environment and the macroeconomic indicators. It analyzes government stability and economic growth of the country.
√ Competitor Assessment
This section compares the major competitors in the industry. The Competitors At-a-Glance is aimed at giving an overview of the competitive landscape in the industry.
√ Company Profiles
The major companies are profiled in this section. For each company, business description is given followed by financial highlights and recent developments.
√ Industry Outlook
This section presents the outlook of the industry. The analyst opinion and projections help us in evaluating the future of the industry. It gives an insight into the investment opportunities present in the sector.

Extracts from Datamonitor
Industry: Biotechnology
Company:Vertex Pharmaceuticals Incorporated
Premium Company Profile
Introduction
Vertex is the inventor of structure based drug design for the discovery and development of small molecule drugs. The company has a drug discovery platform integrating biology, chemistry, biophysics, automation, and information technology.

Scope of this report
√ Contains corporate strategy, value chain presence and SWOT Analysis.
√ Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors.
√ Includes information on suppliers/ partners, shareholding structure and key employees with biographies.

Research and analysis highlights
Apart from its approved product, Vertex has a number of product candidates in its pipeline for HCV infection, rheumatoid arthritis and cancer. Among them, telaprevir for HCV infection, which is being co-developed with Janssen, is the company's lead product candidate.
During 2002-2006, Vertex earned revenues from royalty payments and collaborative agreements. The company's total revenues grew at a double digit CAGR of 23% during 2002-2006 from $95 million in 2002 to $216 million, representing an absolute growth of +$122 million.
The company is forecast to record revenues of $641 million by 2010, growing at a CAGR of 31%. This represents an absolute growth of +$425 million during 2006-2010.

Key reasons to read this report
√ Access all the important information and analysis on the company in a single report.
√ Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain.
√ Gain access to company's adjusted five year financial data along with key ratios and market capitalization.

Industry: Pharmaceuticals and Healthcare
Company: GlaxoSmithKline (GSK)
Company Overview
GlaxoSmithKline (GSK) develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter (OTC) medicines and health related consumer products. The company operates primarily in 117 countries and its products are sold in over 140 countries. It is headquartered in Brentford, the UK and employs about 101,800 people.
The company recorded revenues of £23,225 million during the fiscal year ended December 2006, an increase of 7.2% over 2005. The operating profit of the company was £7,808 million during fiscal year 2006, an increase of 13.6% over 2005.
The net profit was £5,389 million in fiscal year 2006, an increase of 14.9% over 2005.

Conclusion
To an investor looking for capital gain would have more likely to invest in Vertex as it's young, innovative, growing company while the one looking for dividends would more likely to invest in GSK, a large, multinational, mature company.